Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | USP2 | O75604 | 2/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26629419 | 1.00 | ALDH1A1 (0.50) | ALDH1A1POLBGAAUSP2CYP2D6 | |
| SCHEMBL25484796 | 0.89 | ALDH1A1 (0.48) | ALDH1A1POLBGAAUSP2CYP2D6 | |
| SCHEMBL5595399 | 0.86 | ALDH1A1 (0.67) | ALDH1A1GAAUSP2CYP2D6MEN1 | |
| SCHEMBL2105387 | 0.86 | ALDH1A1 (0.67) | ALDH1A1GAAUSP2CYP2D6MEN1 | |
| SCHEMBL2105390 | 0.86 | ALDH1A1 (0.67) | ALDH1A1GAAUSP2CYP2D6MEN1 | |
| SCHEMBL24524718 | 0.86 | ALDH1A1 (0.67) | ALDH1A1GAAUSP2CYP2D6MEN1 | |
| SCHEMBL25774613 | 0.86 | ALDH1A1 (0.67) | ALDH1A1GAAUSP2CYP2D6MEN1 | |
| SCHEMBL23556287 | 0.80 | POLB (0.46) | ALDH1A1POLBGAAUSP2CYP2D6 | |
| SCHEMBL2103737 | 0.80 | POLB (0.46) | ALDH1A1POLBGAAUSP2CYP2D6 | |
| SCHEMBL2103733 | 0.80 | POLB (0.46) | ALDH1A1POLBGAAUSP2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2773639-B1 | ALKYLATED PIPERAZINE COMPOUNDS AS INHIBITORS OF BTK ACTIVITY | HOFFMANN LA ROCHE (CH) | 2017-04-26 | — | — | EP | disclosed |
| US-9115152-B2 | Alkylated piperazine compounds | GENENTECH, INC. (US) | 2015-08-25 | — | — | US | disclosed |
| US-20150094302-A1 | ALKYLATED PIPERAZINE COMPOUNDS | GENENTECH, INC. (US) | 2015-04-02 | — | — | US | disclosed |
| US-8946213-B2 | Alkylated piperazine compounds | GENENTECH, INC. (US) | 2015-02-03 | — | — | US | disclosed |
| EP-2773639-A1 | ALKYLATED PIPERAZINE COMPOUNDS AS INHIBITORS OF BTK ACTIVITY | F.HOFFMANN-LA ROCHE AG (CH) | 2014-09-10 | — | — | EP | disclosed |
| US-20140221365-A1 | ALKYLATED PIPERAZINE COMPOUNDS | GENENTECH, INC. (US) | 2014-08-07 | — | — | US | disclosed |
| US-8729072-B2 | Alkylated piperazine compounds | F. HOFFMAN-LA ROCHE AG (CH) | 2014-05-20 | — | — | US | disclosed |
| WO-2013067277-A1 | ALKYLATED PIPERAZINE COMPOUNDS AS INHIBITORS OF BTK ACTIVITY | GENENTECH, INC. (US) | 2013-05-10 | — | — | WO | disclosed |
| US-20130116245-A1 | ALKYLATED PIPERAZINE COMPOUNDS | GENENTECH, INC. (US) | 2013-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140221365-A1 | ALKYLATED PIPERAZINE COMPOUNDS | BTK, SYK, LCK | ALDH1A1 3275/4885POLB 1560/4885GAA 2924/4885 |
| US-20130116245-A1 | ALKYLATED PIPERAZINE COMPOUNDS | BTK, SYK, LCK | ALDH1A1 3511/4885POLB 1481/4885GAA 3038/4885 |
| US-20150094302-A1 | ALKYLATED PIPERAZINE COMPOUNDS | BTK, SYK, LCK | ALDH1A1 3275/4885POLB 1560/4885GAA 2924/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.